Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol

NCT06764238 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1800

Enrollment

OTHER

Sponsor class

Conditions

Acute Lymphoblastic Leukemia ALL
Childhood Leukemia, Acute Lymphoblastic
B Cell Acute Lymphoblastic Leukemia (B-ALL)

Interventions

DRUG: Blinatumomab (Group A)
DRUG: Venetoclax (nonRand Group)
DRUG: Blinatumomab (Group B)

Sponsor

Institute of Hematology & Blood Diseases Hospital, China